Published in J Am Med Inform Assoc on October 21, 2010
Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc (2011) 2.65
Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes. J Biomed Semantics (2012) 1.83
Multilingual Medical Data Models in ODM Format: A Novel Form-based Approach to Semantic Interoperability between Routine Healthcare and Clinical Research. Appl Clin Inform (2012) 1.28
Drug safety surveillance using de-identified EMR and claims data: issues and challenges. J Am Med Inform Assoc (2010) 1.21
Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc (2012) 1.09
Clinical research informatics: a conceptual perspective. J Am Med Inform Assoc (2012) 1.06
Desiderata for computable representations of electronic health records-driven phenotype algorithms. J Am Med Inform Assoc (2015) 1.04
Signal detection and monitoring based on longitudinal healthcare data. Pharmaceutics (2012) 1.00
ADEpedia 2.0: Integration of Normalized Adverse Drug Events (ADEs) Knowledge from the UMLS. AMIA Jt Summits Transl Sci Proc (2013) 0.92
Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc (2015) 0.83
Computational Drug Repositioning Using Continuous Self-Controlled Case Series. KDD (2016) 0.82
Computational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworks. Drug Saf (2015) 0.79
A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical records. Clin Epidemiol (2015) 0.77
Cross border semantic interoperability for clinical research: the EHR4CR semantic resources and services. AMIA Jt Summits Transl Sci Proc (2016) 0.75
Biobanking informatics infrastructure to support clinical and translational research. AMIA Jt Summits Transl Sci Proc (2013) 0.75
Integrated precision medicine: the role of electronic health records in delivering personalized treatment. Wiley Interdiscip Rev Syst Biol Med (2017) 0.75
Improving postapproval drug safety surveillance: getting better information sooner. Annu Rev Pharmacol Toxicol (2014) 0.75
Cohort restriction based on prior enrollment: Examining potential biases in estimating cancer and mortality risk. Obs Stud (2016) 0.75
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 9.88
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet (2002) 5.17
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med (2006) 2.74
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 2.49
COX-2 inhibitors--lessons in drug safety. N Engl J Med (2005) 2.39
Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf (2006) 2.38
Drug safety. Gaps in the safety net. Science (2005) 2.35
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med (2003) 2.18
Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf (2005) 2.00
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol (2006) 1.90
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation (2004) 1.87
Limitations and strengths of spontaneous reports data. Clin Ther (1998) 1.84
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis (2007) 1.68
The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med (2007) 1.60
Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf (2007) 1.35
Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord (2007) 1.27
What is the harm-benefit ratio of Cox-2 inhibitors? Int J Epidemiol (2008) 1.16
Beyond debacle and debate: developing solutions in drug safety. Nat Rev Drug Discov (2009) 1.13
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med (2005) 1.08
Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther (2007) 1.08
Evaluating drug effects in the post-Vioxx world: there must be a better way. Circulation (2006) 0.99
Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. Med Care (2008) 0.91
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf (2007) 0.91
Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf (2006) 0.90
Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations. Pharmacoepidemiol Drug Saf (2009) 0.84
Semi-automated risk estimation using large databases: quinolones and Clostridium difficile associated diarrhea. Pharmacoepidemiol Drug Saf (2010) 0.82
Postmarketing safety reports for human drug and biological products; electronic submission requirements. Final rule. Fed Regist (2014) 0.81
Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis. Drug Saf (2004) 0.80
Merck withdraws Vioxx; FDA issues public health advisory. FDA Consum (2004) 0.78
Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med (2010) 4.32
Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc (2011) 2.65
Desideratum for evidence based epidemiology. Drug Saf (2013) 1.99
Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol (2013) 1.83
Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med (2013) 1.72
Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Int J Med Inform (2009) 1.68
A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data. Pharmacoepidemiol Drug Saf (2013) 1.48
Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. Pharmacoepidemiol Drug Saf (2006) 1.47
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf (2014) 1.13
Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform (2012) 1.10
An evaluation of three signal-detection algorithms using a highly inclusive reference event database. Drug Saf (2009) 1.10
Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol (2007) 1.05
Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf (2012) 1.03
Intensive lifestyle modification: impact on cardiovascular disease risk factors in subjects with and without clinical cardiovascular disease. Prev Cardiol (2004) 1.00
Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Saf (2013) 0.99
Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics (2013) 0.96
Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation (2003) 0.93
Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Serv Outcomes Res Methodol (2012) 0.92
Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant (2003) 0.92
Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant (2005) 0.89
Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant (2004) 0.88
Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain (2013) 0.88
Alternative outcome definitions and their effect on the performance of methods for observational outcome studies. Drug Saf (2013) 0.87
Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System. Drug Saf (2009) 0.87
Assessment of case definitions for identifying acute liver injury in large observational databases. Drug Saf (2013) 0.85
Systematic investigation of time windows for adverse event data mining for recently approved drugs. J Clin Pharmacol (2009) 0.83
Semi-automated risk estimation using large databases: quinolones and Clostridium difficile associated diarrhea. Pharmacoepidemiol Drug Saf (2010) 0.82
Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients. Nephrol Dial Transplant (2004) 0.82
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. Int Clin Psychopharmacol (2015) 0.82
Patterns in nursing home medication errors: disproportionality analysis as a novel method to identify quality improvement opportunities. Pharmacoepidemiol Drug Saf (2010) 0.82
Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey. Drug Saf (2013) 0.81
Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf (2013) 0.81
Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf (2013) 0.81
Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf (2013) 0.81
Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature. Biostatistics (2013) 0.80
Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system. Drug Saf (2013) 0.80
Managing data quality for a drug safety surveillance system. Drug Saf (2013) 0.79
Surfactant replacement for ventilator-associated pneumonia: a preliminary report. Respiration (2002) 0.77
Design and validation of a data simulation model for longitudinal healthcare data. AMIA Annu Symp Proc (2011) 0.77
Authors' reply to Hennessy and Leonard's comment on "Desideratum for evidence-based epidemiology". Drug Saf (2015) 0.75
Response to comment on 'empirical assessment of methods for risk identification in healthcare data'. Stat Med (2013) 0.75
The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system. Drug Saf (2013) 0.75
Atypical Antipsychotics and the Risk of Falls and Fractures Among Older Adults: An Emulation Analysis and an Evaluation of Additional Confounding Control Strategies. J Clin Psychopharmacol (2017) 0.75